Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.53

-1.6324 (-9.51%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

11:02
11/30/16
11/30
11:02
11/30/16
11:02

Takeda could be 'lured back' if Valeant increases Salix disclosures, FT says

After the Wall Street Journal reported that Valeant (VRX) and Takeda Pharmaceutical (TKPYY)have come to an impasse over the potential price of Salix in a sale, Financial Times reports that a person briefed about the deal said that Takeda "could be lured back to the table" if Valeant discloses more information about Salix's financials and business. Valeant shares are off their earlier lows, but remain down about 8% near 11 am ET. Reference Link

VRX

Valeant

$15.53

-1.6324 (-9.51%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$15.53

-1.6324 (-9.51%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$79.70

0.09 (0.11%)

09:31
09/25/17
09/25
09:31
09/25/17
09:31
Hot Stocks
Daimler Trucks tests truck platooning on public highways in the U.S. »

As the first commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPZ

Williams Partners

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Initiation
Williams Partners initiated  »

Williams Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMB

Williams

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Initiation
Williams initiated  »

Williams initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUM

Yum! Brands

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Recommendations
Yum! Brands analyst commentary  »

Yum! Brands' Taco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

ICPT

Intercept

$61.59

-12.11 (-16.43%)

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Hot Stocks
Intercept says talks with FDA 'evolving' »

When asked on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMMF

Summit Financial Group

$25.01

0.22 (0.89%)

09:30
09/25/17
09/25
09:30
09/25/17
09:30
Downgrade
Summit Financial Group rating change  »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCMI

PCM, Inc.

$13.20

0.2 (1.54%)

09:29
09/25/17
09/25
09:29
09/25/17
09:29
Hot Stocks
PCM, Inc. acquires Stack Technology, subsidiaries »

PCM, Inc. has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

BIIB

Biogen

$318.46

3.43 (1.09%)

, NVO

Novo Nordisk

09:28
09/25/17
09/25
09:28
09/25/17
09:28
Hot Stocks
Biogen apponts Camille Lee as SVP, Alzheimer's Disease Therapeutic Area »

Biogen (BIIB) announced…

BIIB

Biogen

$318.46

3.43 (1.09%)

NVO

Novo Nordisk

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:27
09/25/17
09/25
09:27
09/25/17
09:27
Conference/Events
Wells Fargo financial team holds an analyst/industry conference call »

Wells Fargo Financial…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, PTN

Palatin

09:24
09/25/17
09/25
09:24
09/25/17
09:24
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Exelixis (EXEL),…

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

PTN

Palatin

AGN

Allergan

ICPT

Intercept

$61.59

-12.11 (-16.43%)

GPC

Genuine Parts

TGT

Target

LLY

Eli Lilly

AAPL

Apple

$151.89

-1.5 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

TSLA

Tesla

$351.09

-15.39 (-4.20%)

, GM

General Motors

09:24
09/25/17
09/25
09:24
09/25/17
09:24
Periodicals
China may ease foreign automaker rules aiding Tesla, WSJ reports »

China officials may ease…

TSLA

Tesla

$351.09

-15.39 (-4.20%)

GM

General Motors

VLKAY

Volkswagen

$34.57

0.46 (1.35%)

F

Ford

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 03

    Oct

  • 26

    Oct

SBRA

Sabra Health Care

$22.21

0.03 (0.14%)

09:23
09/25/17
09/25
09:23
09/25/17
09:23
Initiation
Sabra Health Care initiated  »

Sabra Health Care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

09:20
09/25/17
09/25
09:20
09/25/17
09:20
General news
Treasury Action: supply is on tap this week »

Treasury Action: supply…

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/25/17
09/25
09:18
09/25/17
09:18
Options
Overnight activity included 98 trades in SPX and 33 trades in VIX »

98 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$24.50

1.04 (4.43%)

09:17
09/25/17
09/25
09:17
09/25/17
09:17
Recommendations
Nutanix analyst commentary  »

Nutanix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

09:16
09/25/17
09/25
09:16
09/25/17
09:16
Hot Stocks
Amazon signs first-look production deal with Casey Affleck's Sea Change Media »

Amazon Studios has closed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

09:15
09/25/17
09/25
09:15
09/25/17
09:15
General news
The Hurricane Lift for U.S. Producer Sentiment Has Begun: »

The Hurricane Lift for…

TUWOY

Tullow Oil

$1.19

0.08 (7.21%)

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Upgrade
Tullow Oil rating change  »

Tullow Oil upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$151.89

-1.5 (-0.98%)

, S

Sprint

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Recommendations
Apple, Sprint, STMicroelectronics analyst commentary  »

Initial Apple iPhone 8…

AAPL

Apple

$151.89

-1.5 (-0.98%)

S

Sprint

STM

STMicroelectronics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

  • 16

    May

FINL

Finish Line

$9.73

0.51 (5.53%)

09:14
09/25/17
09/25
09:14
09/25/17
09:14
Recommendations
Finish Line analyst commentary  »

Finish Line takeout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.33

-0.12 (-0.19%)

09:13
09/25/17
09/25
09:13
09/25/17
09:13
Recommendations
Carnival analyst commentary  »

Carnival estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

YUM

Yum! Brands

09:13
09/25/17
09/25
09:13
09/25/17
09:13
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

09:12
09/25/17
09/25
09:12
09/25/17
09:12
Hot Stocks
Amazon signs multi-year deal with Amy Sherman-Palladino, Daniel Palladino »

Amazon announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

MSM

MSC Industrial

09:11
09/25/17
09/25
09:11
09/25/17
09:11
Initiation
MSC Industrial initiated  »

MSC Industrial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

LH

LabCorp

, DGX

Quest Diagnostics

09:10
09/25/17
09/25
09:10
09/25/17
09:10
Recommendations
LabCorp, Quest Diagnostics analyst commentary  »

LabCorp, Quest should be…

LH

LabCorp

DGX

Quest Diagnostics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.